The First Condor Group is a biotechnology company integrating cell storage, research and development, production and promotion. With "precision medicine" as the core, the Group has built industrial clusters such as cell cryopreservation, cell medicine and development, and regenerative medicine, etc. Its business covers the upper, middle and lower reaches of the cell industry, establishing an industry with a full production chain. The group owns 3"national high-tech enterprises" .
A total of more than 150 patent applications
Nearly 500 employees
With more than 10,000 square meters of GMP-like laboratory
Shenzhen First Condor Life Sciences Co., Ltd.
Shenzhen First Condor Life Sciences Co., Ltd. (referred to as "First Condor Life"), established in March 2020, is a biopharmaceutical company focusing on the research and industrialization of cell immunotherapy for solid tumors. The company takes the independent research and development of CAR-T products as its forerunner, and simultaneously taps into international cutting-edge technologies such as CAR-NK and CAR-iT. The company has developed three technology platforms with independent intellectual property rights: Trans-CAR®, Boost-CAR®, and R-Star, and has carried out clinical research on solid tumor CAR-T targeting CLDN18.2 and GUCY2C targets in a number of Grade A tertiary hospitals.